Trial Profile
Acute sleep deprivation: The effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2012
Price :
$35
*
At a glance
- Drugs CX 717 (Primary)
- Indications Sleep deprivation; Sleep disorders
- Focus Therapeutic Use
- Sponsors Cortex Pharmaceuticals
- 05 Nov 2010 New trial record.